Cargando…

Anticancer Activity and Cisplatin Binding Ability of Bis-Quinoline and Bis-Isoquinoline Derived [Pd(2)L(4)](4+) Metallosupramolecular Cages

New bis-quinoline (L(q)) and bis-isoquinoline-based (L(iq)) ligands have been synthesized, along with their respective homoleptic [Pd(2)(L(q) or L(iq))(4)](4+) cages (C(q) and C(iq)). The ligands and cages were characterized by (1)H, (13)C and diffusion ordered (DOSY) NMR spectroscopies, high resolu...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasdev, Roan A. S., Gaudin, Lachlan F., Preston, Dan, Jogy, Jackmil P., Giles, Gregory I., Crowley, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262750/
https://www.ncbi.nlm.nih.gov/pubmed/30525025
http://dx.doi.org/10.3389/fchem.2018.00563
_version_ 1783375174591053824
author Vasdev, Roan A. S.
Gaudin, Lachlan F.
Preston, Dan
Jogy, Jackmil P.
Giles, Gregory I.
Crowley, James D.
author_facet Vasdev, Roan A. S.
Gaudin, Lachlan F.
Preston, Dan
Jogy, Jackmil P.
Giles, Gregory I.
Crowley, James D.
author_sort Vasdev, Roan A. S.
collection PubMed
description New bis-quinoline (L(q)) and bis-isoquinoline-based (L(iq)) ligands have been synthesized, along with their respective homoleptic [Pd(2)(L(q) or L(iq))(4)](4+) cages (C(q) and C(iq)). The ligands and cages were characterized by (1)H, (13)C and diffusion ordered (DOSY) NMR spectroscopies, high resolution electrospray ionization mass spectrometry (HR-ESIMS) and in the case of the bis-quinoline cage, X-ray crystallography. The crystal structure of the C(q) architecture showed that the [Pd(2)(L(q))(4)](4+) cage formed a twisted meso isomer where the [Pd(quinoline)(4)](2+) units at either end of the cage architecture adopt the opposite twists (left and right handed). Conversely, Density Functional Theory (DFT) calculations on the C(iq) cage architecture indicated that a lantern shaped conformation, similar to what has been observed before for related [Pd(2)(L(tripy))(4)](4+) systems (where L(tripy) = 2,6-bis(pyridin-3-ylethynyl)pyridine), was generated. The different cage conformations manifest different properties for the isomeric cages. The C(iq) cage is able to bind, weakly in acetonitrile, the anticancer drug cisplatin whereas the C(q) architecture shows no interaction with the guest under the same conditions. The kinetic robustness of the two cages in the presence of Cl(−) nucleophiles was also different. The C(iq) cage was completely decomposed into free L(iq) and [Pd(Cl)(4)](2−) within 1 h. However, the C(q) cage was more long lived and was only fully decomposed after 7 h. The new ligands (L(iq) and L(q)) and the Pd(II) cage architectures (C(iq) and C(q)) were assessed for their cytotoxic properties against two cancerous cell lines (A549 lung cancer and MDA-MB-231 breast cancer) and one non-cancerous cell line (HDFa skin cells). It was found that L(q) and C(q) were both reasonably cytotoxic (IC(50S) ≈ 0.5 μM) against A549, while C(iq) was slightly less active (IC(50) = 7.4 μM). L(iq) was not soluble enough to allow the IC(50) to be determined against either of the two cancerous cell lines. However, none of the molecules showed any selectivity for the cancer cells, as they were all found to have similar cytotoxicities against HDFa skin cells (IC(50) values ranged from 2.6 to 3.0 μM).
format Online
Article
Text
id pubmed-6262750
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62627502018-12-06 Anticancer Activity and Cisplatin Binding Ability of Bis-Quinoline and Bis-Isoquinoline Derived [Pd(2)L(4)](4+) Metallosupramolecular Cages Vasdev, Roan A. S. Gaudin, Lachlan F. Preston, Dan Jogy, Jackmil P. Giles, Gregory I. Crowley, James D. Front Chem Chemistry New bis-quinoline (L(q)) and bis-isoquinoline-based (L(iq)) ligands have been synthesized, along with their respective homoleptic [Pd(2)(L(q) or L(iq))(4)](4+) cages (C(q) and C(iq)). The ligands and cages were characterized by (1)H, (13)C and diffusion ordered (DOSY) NMR spectroscopies, high resolution electrospray ionization mass spectrometry (HR-ESIMS) and in the case of the bis-quinoline cage, X-ray crystallography. The crystal structure of the C(q) architecture showed that the [Pd(2)(L(q))(4)](4+) cage formed a twisted meso isomer where the [Pd(quinoline)(4)](2+) units at either end of the cage architecture adopt the opposite twists (left and right handed). Conversely, Density Functional Theory (DFT) calculations on the C(iq) cage architecture indicated that a lantern shaped conformation, similar to what has been observed before for related [Pd(2)(L(tripy))(4)](4+) systems (where L(tripy) = 2,6-bis(pyridin-3-ylethynyl)pyridine), was generated. The different cage conformations manifest different properties for the isomeric cages. The C(iq) cage is able to bind, weakly in acetonitrile, the anticancer drug cisplatin whereas the C(q) architecture shows no interaction with the guest under the same conditions. The kinetic robustness of the two cages in the presence of Cl(−) nucleophiles was also different. The C(iq) cage was completely decomposed into free L(iq) and [Pd(Cl)(4)](2−) within 1 h. However, the C(q) cage was more long lived and was only fully decomposed after 7 h. The new ligands (L(iq) and L(q)) and the Pd(II) cage architectures (C(iq) and C(q)) were assessed for their cytotoxic properties against two cancerous cell lines (A549 lung cancer and MDA-MB-231 breast cancer) and one non-cancerous cell line (HDFa skin cells). It was found that L(q) and C(q) were both reasonably cytotoxic (IC(50S) ≈ 0.5 μM) against A549, while C(iq) was slightly less active (IC(50) = 7.4 μM). L(iq) was not soluble enough to allow the IC(50) to be determined against either of the two cancerous cell lines. However, none of the molecules showed any selectivity for the cancer cells, as they were all found to have similar cytotoxicities against HDFa skin cells (IC(50) values ranged from 2.6 to 3.0 μM). Frontiers Media S.A. 2018-11-22 /pmc/articles/PMC6262750/ /pubmed/30525025 http://dx.doi.org/10.3389/fchem.2018.00563 Text en Copyright © 2018 Vasdev, Gaudin, Preston, Jogy, Giles and Crowley. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Chemistry
Vasdev, Roan A. S.
Gaudin, Lachlan F.
Preston, Dan
Jogy, Jackmil P.
Giles, Gregory I.
Crowley, James D.
Anticancer Activity and Cisplatin Binding Ability of Bis-Quinoline and Bis-Isoquinoline Derived [Pd(2)L(4)](4+) Metallosupramolecular Cages
title Anticancer Activity and Cisplatin Binding Ability of Bis-Quinoline and Bis-Isoquinoline Derived [Pd(2)L(4)](4+) Metallosupramolecular Cages
title_full Anticancer Activity and Cisplatin Binding Ability of Bis-Quinoline and Bis-Isoquinoline Derived [Pd(2)L(4)](4+) Metallosupramolecular Cages
title_fullStr Anticancer Activity and Cisplatin Binding Ability of Bis-Quinoline and Bis-Isoquinoline Derived [Pd(2)L(4)](4+) Metallosupramolecular Cages
title_full_unstemmed Anticancer Activity and Cisplatin Binding Ability of Bis-Quinoline and Bis-Isoquinoline Derived [Pd(2)L(4)](4+) Metallosupramolecular Cages
title_short Anticancer Activity and Cisplatin Binding Ability of Bis-Quinoline and Bis-Isoquinoline Derived [Pd(2)L(4)](4+) Metallosupramolecular Cages
title_sort anticancer activity and cisplatin binding ability of bis-quinoline and bis-isoquinoline derived [pd(2)l(4)](4+) metallosupramolecular cages
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262750/
https://www.ncbi.nlm.nih.gov/pubmed/30525025
http://dx.doi.org/10.3389/fchem.2018.00563
work_keys_str_mv AT vasdevroanas anticanceractivityandcisplatinbindingabilityofbisquinolineandbisisoquinolinederivedpd2l44metallosupramolecularcages
AT gaudinlachlanf anticanceractivityandcisplatinbindingabilityofbisquinolineandbisisoquinolinederivedpd2l44metallosupramolecularcages
AT prestondan anticanceractivityandcisplatinbindingabilityofbisquinolineandbisisoquinolinederivedpd2l44metallosupramolecularcages
AT jogyjackmilp anticanceractivityandcisplatinbindingabilityofbisquinolineandbisisoquinolinederivedpd2l44metallosupramolecularcages
AT gilesgregoryi anticanceractivityandcisplatinbindingabilityofbisquinolineandbisisoquinolinederivedpd2l44metallosupramolecularcages
AT crowleyjamesd anticanceractivityandcisplatinbindingabilityofbisquinolineandbisisoquinolinederivedpd2l44metallosupramolecularcages